Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 24, 2017
What is the competitive landscape for PHARMACIA, and when can generic versions of PHARMACIA drugs launch?
PHARMACIA has one hundred and thirty-seven approved drugs.| Patents: | 9 |
| Tradenames: | 111 |
| Ingredients: | 86 |
| NDAs: | 137 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacia And Upjohn | NEO-DELTA-CORTEF | neomycin sulfate; prednisolone acetate | OINTMENT;OPHTHALMIC | 061039-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Pharmacia And Upjohn | CLEOCIN HYDROCHLORIDE | clindamycin hydrochloride | CAPSULE;ORAL | 050162-003 | Apr 14, 1988 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Pharmacia And Upjohn | VANTIN | cefpodoxime proxetil | TABLET;ORAL | 050674-001 | Aug 7, 1992 | DISCN | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Pharmacia And Upjohn | DIDREX | benzphetamine hydrochloride | TABLET;ORAL | 012427-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Pharmacia And Upjohn | CYKLOKAPRON | tranexamic acid | TABLET;ORAL | 019280-001 | Dec 30, 1986 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacia And Upjohn | HALCION | triazolam | TABLET;ORAL | 017892-001 | Nov 15, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pharmacia And Upjohn | PROSTIN E2 | dinoprostone | SUPPOSITORY;VAGINAL | 017810-001 | Approved Prior to Jan 1, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pharmacia And Upjohn | GLYNASE | glyburide | TABLET;ORAL | 020051-004 | Sep 24, 1993 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pharmacia And Upjohn | PREPIDIL | dinoprostone | GEL;ENDOCERVICAL | 019617-001 | Dec 9, 1992 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Pharmacia And Upjohn | ZYVOX | linezolid | FOR SUSPENSION;ORAL | 021132-001 | Apr 18, 2000 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
linezolid | Injection | 2 mg/mL, 100 mL bag | ZYVOX | 12/29/2009 |
linezolid | Injection | 2 mg/mL, 300 mL bag | ZYVOX | 9/1/2009 |
linezolid | Oral Suspension | 100 mg/5 mL | ZYVOX | 8/3/2009 |
tolterodine tartrate | Extended-release Capsules | 2 mg and 4 mg | DETROL LA | 7/30/2007 |
linezolid | Tablets | 600 mg | ZYVOX | 12/21/2005 |
colestipol hydrochloride | Tablets | 1 g | COLESTID | 8/23/2005 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,821,047 | Monovalent phage display | ► Subscribe | |||||||||||||||||||||||||||
| 6,013,478 | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | ► Subscribe | |||||||||||||||||||||||||||
| 6,780,613 | Growth hormone variants | ► Subscribe | |||||||||||||||||||||||||||
| 8,637,646 | Growth hormone variants | ► Subscribe | |||||||||||||||||||||||||||
| 5,955,346 | Variants of human prolactin and human placeatal lactogen | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 9927983 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2001267371 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2400118 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2006104205 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 20070087178 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 00016 | Denmark | ► Subscribe | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 | ||||||||||||||||||||||||||
| C/GB05/047 | United Kingdom | ► Subscribe | PRODUCT NAME: PEGVISOMANT, OPTIONALLY IN THE FORM OF A PEGYLATION VARIANT; REGISTRATION NO/DATE: EU/1/02/240/001 - 003 20021113 | ||||||||||||||||||||||||||
| C0005 | France | ► Subscribe | PRODUCT NAME: LINEZOLIDE; NAT. REGISTRATION NO/DATE: NL 26 660 20010831; FIRST REGISTRATION: GB - PL 00 32/0261 20010105 | ||||||||||||||||||||||||||
| 2009004,C0770388 | Lithuania | ► Subscribe | PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103 | ||||||||||||||||||||||||||
| 1304992/01 | Switzerland | ► Subscribe | PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,099 others who get our Drug Patent Expiration Alerts:
